CoChat

Hormone replacement therapy to maintain cognitive function in women with dementia

Open access
Hogervorst, Eva, Yaffe, Kristine, Richards, Marcus, Huppert, Felicia AH · 2009 · Cochrane Database of Systematic Reviews
Cited by 153

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: As estrogens have been shown to have several potentially beneficial effects on the central nervous system, it is biologically plausible that maintaining high levels of estrogens in postmenopausal women by means of estrogen replacement therapy (ERT) could be protective against cognitive decline in women with Alzheimer's disease (AD) or other dementia syndromes. OBJECTIVES: To investigate the effects of ERT (estrogens only) or HRT (estrogens combined with a progestagen) compared with placebo in randomized controlled trials (RCTs) on cognitive function of postmenopausal women with dementia. SEARCH STRATEGY: The Cochrane Dementia and Cognitive Improvement Group Specialized Register, which contains records from many medical databases, The Cochrane Library, EMBASE, MEDLINE, CINAHL, PsycINFO and LILACS were searched on 7 November 2007 using the terms ORT, PORT, ERT, HRT, estrogen*, oestrogen* and progesterone*. SELECTION CRITERIA: All double-blind randomized controlled trials (RCTs) into the effect of ERT or HRT for cognitive function with a treatment period of at least two weeks in postmenopausal women with AD or other types of dementia. DATA COLLECTION AND ANALYSIS: Abstracts of the references retrieved by the searches were read by two reviewers (EH and KY) independently in order to discard those that were clearly not eligible for inclusion. The two reviewers studied the full text of the remaining references and independently selected studies for inclusion. Any disparity in the ensuing lists was resolved by discussion with all reviewers in order to arrive at the final list of included studies. The selection criteria ensured that the blinding and randomization of the included studies was adequate. The two reviewers also assessed the quality of other aspects of the included trials. One reviewer (EH) extracted the data from the studies, but was aided and checked by JB from Cochrane. MAIN RESULTS: A total of seven trials including 351 women with AD were analysed. Because different drugs were used at different studies it was not possible to combine more than two studies in any analysis.On a clinical global rating, clinicians scored patients taking CEE as significantly worse compared with the placebo group on the Clinical Dementia Rating scale after 12 months (overall WMD = 0.35, 95% CI = 0.01 to 0.69, z = 1.99, P < 0.05).Patients taking CEE had a worse performance on the delayed recall of the Paragraph Test (overall WMD = -0.45, 95% CI = -0.79 to -0.11, z = 2.60, P < 0.01) after one month than those taking placebo. They had a worse performance on Finger Tapping after 12 months (WMD = -3.90, 95% CI = -7.85 to 0.05, z = 1.93, P < 0.05).Limited positive effects were found for the lower dosage of CEE (0.625 mg/day) which showed a significant improvement in MMSE score only when assessed at two months, and disappeared after correction for multiple testing. No significant effects for MMSE were found at longer end points (3, 6 and 12 months of treatment). With a dosage of 1.25 mg/d CEE, short-term significant effects were found for Trial-Making test B at one month and Digit Span backward at four months. After two months of transdermal diestradiol (E2) treatment, a highly significant effect was observed for the word recall test (WMD = 6.50, 95% CI = 4.04 to 8.96, z = 5.19, P < 0.0001). No other significant effects were found for other outcomes measured. AUTHORS' CONCLUSIONS: Currently, HRT or ERT for cognitive improvement or maintenance is not indicated for women with AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd003799.pub2

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 47

  1. Asthana, 1999, Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with AD: results of a placebo-controlled, double-blind pilot study, Psychoneuroendocrinology, 24, 657, 10.1016/S0306-4530(99)00020-7 · DOI · Paper page
  2. Asthana S Baker LD Craft S Stanczyk FZ Veith RC Raskind MA Plymate SR High-dose estradiol improves cognition for women with AD: results of a randomized study Neurology 2001 605 12 · DOI · Paper page
  3. Birge, 1997, The role of estrogen in the treatment of Alzheimer's disease, Neurology, 48, S36, 10.1212/WNL.48.5_Suppl_7.36S · DOI · Paper page
  4. Henderson, 2000, Estrogen for Alzheimer's disease in women, Neurology, 54, 295, 10.1212/WNL.54.2.295 · DOI · Paper page
  5. Honjo, 1995, Senile dementia-Alzheimer's type and estrogen, Horm. Metab. Res., 27, 204, 10.1055/s-2007-979941 · DOI · Paper page
  6. Caldwell, 1952, Evaluation of psychologic effects of sex hormone administration in aged women: results of therapy after 6 months, Journal of Gerontology, 7, 228, 10.1093/geronj/7.2.228 · DOI · Paper page
  7. Mulnard, 2000, Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease, JAMA, 283, 1007, 10.1001/jama.283.8.1007 · DOI · Paper page
  8. Wang, 2000, Effects of estrogen on cognition, mood, and cerebral blood flow in AD, Neurology, 54, 2061, 10.1212/WNL.54.11.2061 · DOI · Paper page
  9. Zhang, 2006, Quantitative evaluation of the intervention al effect of estrogen on Alzheimer's disease, Chinese Journal of Clinical Rehabilitation, 10, 37
  10. Fillit, 1986, Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type, Psychoneuroendocrinology, 11, 337, 10.1016/0306-4530(86)90019-3 · DOI · Paper page
  11. Fillit, 1994, Estrogens in the Pathogenesis and Treatment of Alzheimer's Disease in Postmenopausal Women, Annals of the New York Academy of Sciences, 743, 233, 10.1111/j.1749-6632.1994.tb55795.x · DOI
  12. Honjo, 1989, In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type), Journal of Steroid Biochemistry, 34, 521, 10.1016/0022-4731(89)90137-4 · DOI · Paper page
  13. Kantor, 1973, Estrogen for older women, American Journal of Obstetrics and Gynecology, 4, 31
  14. Ohkura, 1994, Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type, Endocrine Journal, 41, 361, 10.1507/endocrj.41.361 · DOI · Paper page
  15. Ohkura, 1994b, Low-dose estrogen replacement therapy for Alzheimer disease in women, Menopause, 1, 125
  16. Ohkura, 1995, Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type 7 case reports, Dementia, 6, 99
  17. Rigaud, 2003, No additional benefit of HRT on response to rivastigmine in menopausal women with AD, Neurology, 60, 148, 10.1212/WNL.60.1.148-a · DOI · Paper page
  18. Al-Azzawi, 2008, Pulsatile nasal administration of estradiol for postmenopausal complaints
  19. American Psychiatric Association, 1999, Diagnostic and Statistical Manual of Mental Disorders
  20. Barrett-Connor, 1991, Postmenopausal estrogen and prevention bias. Postmenopausal estrogen and prevention bias, Annals of Internal Medicine, 115, 455, 10.7326/0003-4819-115-6-455 · DOI · Paper page
  21. Christie, 1990, Reduced plasma oestrogen stimulated neurophysin and delayed response to oestrogen challenge in AD, Psych Med, 20, 773, 10.1017/S003329170003645X · DOI
  22. Col, 2001, Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk, Journal of Clinical Oncology, 19, 2357, 10.1200/JCO.2001.19.8.2357 · DOI
  23. Fratiglioni, 2000, Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group, Neurology, 54, S10
  24. Gibbs, 2008, Animal studies that support estrogen effects on cognitive performance and the cholinergic basis of the critical period hypothesis
  25. Henderson, 2008, The critical window hypothesis: hormone exposure and cognitive outcomes after menopause
  26. Hogervorst, 2000, The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis, Neuroscience, 101, 485, 10.1016/S0306-4522(00)00410-3 · DOI · Paper page
  27. Hogervorst, 2007, Should surgically menopausal women be treated with estrogens to decrease the risk for dementia?, Neurology, Invited Editorial, 69, 1070
  28. Huppert, 1997, Ageing, cognition and dementia, Age and Ageing, Dec 26, 20, 10.1093/ageing/26.suppl_4.20 · doi:10.1093/ageing/26.suppl_4.20
  29. LeBlanc, 2001, Hormone replacement therapy and cognition, JAMA, 285, 1489, 10.1001/jama.285.11.1489 · DOI · Paper page
  30. Lethaby, 2008, Hormone replacement therapy for cognitive function in postmenopausal women, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003122.pub2 · DOI · Paper page
  31. Matthews, 1996, Prior to use of estrogen replacement therapy: are users healthier than nonusers ?, American Journal of Epidemiology, 143, 971, 10.1093/oxfordjournals.aje.a008678 · DOI · Paper page
  32. McEwen, 1997, Ovarian steroids and the brain implications for cognition and aging, Neurology, 48, S14, 10.1212/WNL.48.5_Suppl_7.8S · DOI · Paper page
  33. McKhann, 1984, Clinical Diagnosis of Alzheimer’s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology, 4, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
  34. Nappi, 1999, Memory functioning at menopause: impact of age in ovariectomized women, Gynecologic and Obstetric Investigation, 47, 29, 10.1159/000010058 · DOI · Paper page
  35. Paganini-Hill, 2001, Hormone replacement therapy and stroke: risk, protection or no effect? Hormone replacement therapy and stroke: risk, protection or no effect?, Maturitas, 38, 243, 10.1016/S0378-5122(01)00167-0 · DOI
  36. Rodríguez, 2001, Thiamine for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD001498 · DOI
  37. Schulz, 1995, Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA, 273, 408, 10.1001/jama.1995.03520290060030 · DOI
  38. Schumaker, 1998, The WHIMS: a trial of estrogen therapy in preventing and slowing the progression of dementia, Control Clin Trials, 19, 604
  39. Shumaker, 2004, Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study, JAMA, 291, 2947, 10.1001/jama.291.24.2947 · DOI · Paper page
  40. Silva, 2001, Estrogen and the aging brain, Maturitas, 38, 100, 10.1016/S0378-5122(00)00195-X · DOI
  41. Toran-Allerand, 2000, Estrogen as a treatment for AD: commentary, JAMA, 284, 307, 10.1001/jama.284.3.307-a · doi:10.1001/jama.284.3.307-a
  42. Wegienka, 2006, Menopausal hormone therapy in a health maintenance organization before and after women's health initiative hormone trials termination, Journal of Women's Health, 15, 369, 10.1089/jwh.2006.15.369 · DOI
  43. Yaffe, 1998, Estrogen therapy in postmenopausal women, Journal of the American Medical Association, 279, 688, 10.1001/jama.279.9.688 · DOI · Paper page
  44. Yaffe, 1998, Serum estrogen levels, cognitive performance and risk of cognitive decline in older community women, Journal of the American Geriatrics Sociaty, 46, 816, 10.1111/j.1532-5415.1998.tb02713.x · DOI · Paper page
  45. Yaffe, 2000, Cognitive decline in women with relation to non-protein bound estradiol concentrations, Lancet, 356, 708, 10.1016/S0140-6736(00)02628-3 · DOI · Paper page
  46. Yesufu, 2007, Meta-analyses of the effect of hormone treatment on cognitive function in postmenopausal women, Women’s Health invited review, 3, 173
  47. Hogervorst, 2002, Hormone replacement therapy to maintain cognitive function in women with dementia, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003799 · DOI

Cited by

See all 153

Metadata

Authors
Hogervorst, E., Yaffe, K., Richards, M., & Huppert, F. A.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2009-01-21
Volume
2010
Issue
1
Pages
CD003799-CD003799
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1706937218
Cited by
153
References
4
FWCI
10.00
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hormone replacement therapy to maintain cognitive function in women with dementia. https://app.cochat.ai/papers/10.1002/14651858.cd003799.pub2
The paper
Hogervorst, E., Yaffe, K., Richards, M., & Huppert, F. A. (2009). Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd003799.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.